Ro 08-2750

Research use only, not for human use.

Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM.

Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM. Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM. Ro 08-2750 inhibits NGF binding to p75NTR selectively over TRKA.(In Vitro):Ro 08-2750 inhibits the survival of human AML lines and patient cells. Ro 08-2750 suppresses MSI2 RNA-binding and alters the MSI2 gene signature. Ro 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75NTR anymore. Ro 08-2750 (5-10 μM; 8?hours) increases differentiation and apoptosis in myeloid leukemia cells. Ro 08-2750 (10 nM) fully rescues cells from undergoing NGF-induced SK-N-MC 103 cell death .(In Vivo):In a myeloid leukemia model in vivo, Ro 08-2750 (13.75?mg/kg; i.p.) suppresses leukemogenesis .

——

Others

Other Targets

AhR; Androgen Receptor; Antifungal; Estrogen Receptor/ERR

——

——

37854-59-4

270.2

C13H10N4O3

>98% (HPLC)

——

Cc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O

——

(-20℃)

With Ice Pack

≥ 2 years